DelveInsight’s Psoriasis Market Insights, Epidemiology and Market Forecast 2034 provides the current and forecast market analysis, individual leading Psoriasis Companies market shares, challenges, Psoriasis Market Drivers, barriers, trends, and key market Psoriasis companies in the market.
To read more about the latest highlights related to the Psoriasis Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Key Takeaways from the Psoriasis Market Report
- In March 2025, SFA Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida, demonstrating emerging innovation in the psoriasis therapeutics landscape.
- The Psoriasis market in the 7MM (US, EU4, UK, and Japan) was valued at USD 33,803 million in 2025 and is projected to reach USD 39,239 million by 2034 over the forecast period from 2025 to 2034.
- The Psoriasis market is projected to grow at a CAGR of 1.70% by 2034 in leading countries (US, EU4, UK and Japan).
- Among the 7MM, the US captured the highest psoriasis market with approximately USD 26,740 million in 2024, which is projected to rise by 2034.
- The leading Psoriasis Companies such as UCB Pharma, Novartis, Alumis, SFA Therapeutics, Amgen, AbbVie, Can-Fite BioPharma, Johnson & Johnson Innovative Medicine and Protagonist Therapeutics, and others.
- The leading Psoriasis Companies such as UCB Pharma, Novartis, Alumis, SFA Therapeutics, Amgen, AbbVie, Can-Fite BioPharma, Johnson & Johnson Innovative Medicine and Protagonist Therapeutics, and others.
- The leading Psoriasis Therapies such as SKYRIZI , BIMZELX , TREMFYA , OTEZLA , ESK-001 , SERNIVO , Icotrokinra (JNJ-77242113) , and others.
To know more about why the US is leading the market growth in the Psoriasis Market, get a snapshot @ Psoriasis Market Outlook
Psoriasis Market Dynamics
According to epidemiological data, the global prevalence of psoriasis is increasing, with approximately 125 million people affected worldwide. The total number of diagnosed prevalent cases of psoriasis in the 7MM was approximately 15.8 million in 2024. Psoriasis is a chronic, immune-mediated disease resulting from the overproduction of skin cells accumulating on the skin’s surface, which causes red, scaly plaques that may itch and bleed. The demand for advanced psoriasis therapeutics is rising significantly, driven by the increasing disease prevalence, growing awareness due to the launch of emerging therapies, a growing geriatric population, and advancements in diagnostic approaches. Key factors such as continuous innovations in biologic treatments, including Tumor necrosis factor-alpha (TNF-α) inhibitors, IL-23 inhibitors, and IL-17 inhibitors, are creating a favorable environment for sustained market growth.
Psoriasis Market Segmentation Analysis
Psoriasis Market by Product & Service (Topical treatments, Phototherapy, and Systemic treatments), Type (TNF inhibitors, IL-23 inhibitors, IL-17 inhibitors, PDE4 inhibitors, and TYK2 inhibitors), Deployment (Hospital settings, Specialty clinics, and Outpatient care), Application (Plaque psoriasis, Scalp psoriasis, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). In the type segment of the Psoriasis market, systemic treatments, particularly biologics including IL-23 inhibitors and IL-17 inhibitors, are estimated to account for significant market share in 2024. Scalp psoriasis had the highest occurrence of cases with 4,811,170 cases in the US in 2024, while plaque psoriasis cases were maximum in Germany with 2,099,495 cases in 2024.
Get a sneak peek at the Psoriasis Market Dynamics @ Psoriasis Market Dynamics Analysis
Psoriasis Companies
UCB Pharma, Novartis, Alumis, SFA Therapeutics, Amgen, AbbVie, Can-Fite BioPharma, Johnson & Johnson Innovative Medicine and Protagonist Therapeutics, Takeda/Nimbus Therapeutics, Organon Pharmaceuticals, Sun Pharmaceutical, Almirall, Bausch Health, Boehringer Ingelheim, and LEO Pharma.
Psoriasis Market Drivers
The demand for psoriasis therapeutics is rising significantly, driven by the increasing prevalence of psoriasis, with approximately 125 million people affected globally. The total number of diagnosed prevalent cases in the 7MM was 15.8 million in 2024, with psoriasis predominantly observed in adults, accounting for approximately 97% of all cases. Key factors such as continuous advancements in biologic psoriasis therapies, innovations in oral treatment options, rising disease awareness, and the emergence of novel therapies are creating a favorable environment for sustained market growth. Additionally, treatment switching patterns, wherein patients transition from oral therapies to biologics for better efficacy and tolerability, and the growing emphasis on long-term disease control and quality-of-life improvements are driving market expansion from 2025 to 2034.
Which MedTech key players in the Psoriasis Market are set to emerge as the trendsetter? Explore @ Psoriasis Companies
Scope of the Psoriasis Market Report
- Coverage- 7MM (US, EU4 [Germany, France, Italy, and Spain], UK, and Japan)
- Study Period- 2020–2034
- Forecast Period- 2025–2034
- Psoriasis Companies- UCB Pharma, Novartis, Alumis, SFA Therapeutics, Amgen, AbbVie, Can-Fite BioPharma, Johnson & Johnson Innovative Medicine and Protagonist Therapeutics, Takeda/Nimbus Therapeutics, Organon Pharmaceuticals, and others.
- Psoriasis Therapies- SKYRIZI , BIMZELX , TREMFYA , OTEZLA , ESK-001 , SERNIVO , Icotrokinra (JNJ-77242113) , and others.
Interested in knowing the Psoriasis Market by 2034? Click to get a snapshot of the Psoriasis Market Trends
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Forecast Methodology
- Psoriasis Market Overview at a Glance
- Disease Background and Overview
- Epidemiology and Patient Population of 7MM
- Patient Journey of Psoriasis
- Marketed Therapies
- Emerging Drugs
- Psoriasis: 7MM Analysis
- Unmet Needs
- SWOT Analysis
- KOL Views
- Market Access and Reimbursement
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
